CDMOP.PFD (Avid Bioservices) ROCE % : -22.04% (As of Oct. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Avid Bioservices ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Avid Bioservices's annualized ROCE % for the quarter that ended in Oct. 2024 was -22.04%.

Avid Bioservices ROCE % Historical Data

The historical data trend for Avid Bioservices's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices ROCE % Chart

Avid Bioservices Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

ROCE %

Get a 7-Day Free Trial

-17.67

9.60

5.59

1.56

-8.99

Avid Bioservices Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial															-11.73	-8.11	-5.49	-4.65	-22.04

Avid Bioservices ROCE % Calculation

Avid Bioservices's annualized ROCE % for the fiscal year that ended in Apr. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2024 )		(A: Apr. 2023 )		(A: Apr. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2024 )		(A: Apr. 2023 )		(A: Apr. 2024 )
	=	-22.59	/	( ( (451.567 - 215.146)	+	(336.557 - 70.566) )	/ 2 )
	=	-22.59	/	( (236.421	+	265.991)	/ 2 )
	=	-22.59	/	251.206
	=	-8.99 %

Avid Bioservices's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-56.52	/	( ( (334.642 - 71.082)	+	(323.482 - 74.156) )	/ 2 )
	=	-56.52	/	( ( 263.56	+	249.326 )	/ 2 )
	=	-56.52	/	256.443
	=	-22.04 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

Avid Bioservices (NAS:CDMOP.PFD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Avid Bioservices ROCE % Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avid Bioservices Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMOP.PFD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

14191 Myford Road, Tustin, CA, USA, 92780

Website

https://www.avidbio.com

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.